Executive Summary
Wells Therapeutics Inc. strategically bridges pharmaceutical innovation between China and the United States by co-developing or in-licensing First-in-Class (FIC) and Best-in-Class (BIC) assets from Chinese biotechs.
Through a hybrid operational model and deep clinical expertise, the company accelerates global development strategies by leveraging local China execution and efficacy data to generate clinical Proof-of-Concept (PoC) within just two to three years while significantly lowering the cost of experimentation.
Their paradigm-shifting, world-leading multi-payload ADC pipeline is powered by innovative Chinese platform technology and led by an esteemed global team with decades of experience at top-tier pharmaceutical companies. By maintaining early alignment with major pharma partners, Wells Therapeutics provides clear exit paths and high returns for investors, maximizing both innovation and capital efficacy to deliver breakthrough medicines to patients worldwide
• Bridge China Innovation with global development.
Co-develop with or In-license from China biotech to develop FIC/BIC assets.
• Global strategy accelerated by China efficacy
Generate clinical PoC in 2–3 years; lower cost of trial and error for FIC therapies.
• World-leading multi-payload ADC pipeline
Paradigm-Shifting approach enabled by China platform technology, will be led by an esteemed global team.
• Clear exit paths for high-value assets
A trusted partner to Pharma by early alignment; High return to investors through innovation & capital efficacy.